Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
For the first time, a medicine specifically aimed at treating CF has been included on the EML and the worlds leading health authority has recognised that Trikafta is not a luxury drug, but an essential medicine and that every child and adult living with CF should have the right to access it. The group added: This is a powerful statement from the WHO: not only is Trikafta recognised as essential, but its inclusion is about breaking down barriers to access and ensuring patients everywhere not just in the richest countries can benefit from its lifesaving impact. Balancing innovation, cost, and health system strengthening David Reddy, Director-General of the International Federation of Pharmaceutical Manufacturers and Associations, said that the inclusion of multiple advanced therapies highlights how scientific advances are transforming how we prevent, treat and cure disease, and reinforces the importance of ensuring patients everywhere can benefit from them. However, WHOs expert group has sometimes withheld recommendations for expensive new treatments due to affordability concerns
Plasma peptide YY (PYY) in dumping syndrome
Just more energy and less snacking
The mean change in HbA1c was not different between the two approaches (WMD 0.08%, 95% CI 1.07 to 1.23)
US$ 28.03
US$ 20.87
US$ 23.33
US$ 29.36
US$ 20.25
US$ 21.72
US$ 28.91
